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Abstract. The intestinal barrier, which primarily consists of epithelial cells stitched together with connecting proteins called
tight junctions, plays a critical role in health and disease. It is in close contact with the gut microbiota on its luminal side
and with the enteric neurons on the tissue side. Both microbiota and the enteric nervous system are regulatory housekeepers
of the intestinal barrier. Therefore, the recently observed enteric neuropathology along with gut dysbiosis in Parkinson’s
disease have prompted research on intestinal permeability in this neurodegenerative disorder. In this mini-review we attempt
to concisely summarize the current knowledge on intestinal barrier in Parkinson’s disease. We envision future direction
research that should be pursued in order to demonstrate its possible role in disease development and progression.
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INTRODUCTION
The epithelial lining of the intestine provides a
protective barrier against the potentially hostile envi-
ronment in the lumen of the intestine. It also separates
the commensal microbes that reside at the apical
side of the epithelium in the intestine lumen and
the immune system and enteric nervous system at
the basal side in the underlying tissue. The cells
that make up this epithelial lining are packed closely
together via so-called tight junctions. These ensure
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that nothing leaks through, while distinct composi-
tions of receptors, pumps and channels at apical and
basal surface domains allow regulated communica-
tions between luminal and tissue environments. A
compromised intestinal barrier function has unequiv-
ocally been associated with inflammatory conditions
in the gut. Recently, a compromised intestinal epithe-
lial barrier has also been associated with Parkinson’s
disease (PD), fueling the hypothesis that gut-derived
factors may participate in the pathogenesis of PD. In
this concise article we review the available evidence
for a compromised intestinal barrier in PD patients.
We discuss the possible contribution of intestinal bar-
rier dysfunction to the pathogenesis of PD and its
possible clinical implications, and eventually we pro-
pose directions for future research.
ISSN 1877-7171/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved
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COMPROMISED INTESTINAL BARRIER
FUNCTION IN PD: WHAT IS THE
EVIDENCE?
Analyses of gut wall barrier function in human sub-
jects are typically done via any of three assays. These
include in vivo gut wall permeability tests, in situ
immunolabeling of tight junction proteins, ex vivo
mucosal permeability tests and analyses of proteins
detectable in fecal samples (e.g., alpha-1-antitrypsin,
zonulin) [1]. All assays have been used to investigate
gut wall barrier function in PD patients.
In vivo gut wall permeability tests
Urinary excretion of orally ingested non-
metabolizable sugars of different sizes provides an
easy and non-invasive in vivo read-out of intestinal
barrier function [2, 3]. Measurement of urinary
excretion as a function of time after sugar ingestion
can be used to evaluate the barrier function along the
horizontal axis of the intestine, i.e., from duodenum
to colon. Most commonly used is a combination of a
monosaccharide and disaccharide such as mannitol
(or L-rhamnose) and lactulose, respectively, the
urinary recovery of which is typically measured
within 5 hours after ingestion. The relatively small
sized mannitol easily moves from the gut lumen to
the underlying tissue whereas the larger lactulose
does not. An increase of urinary lactulose output in
combination with an unchanged urinary mannitol
output (which also serves to correct for differences
in gastric emptying) gives rise to an increase in the
lactulose/mannitol ratio. This is interpreted as a
measure of increased permeability of the intestinal
epithelium (Fig. 1).
In 1996 Davies and colleagues [4] used the man-
nitol/lactulose test in 15 PD patients and found an
increase in the lactulose/mannitol ratio in urinary
samples taken 5 hours after ingestion of the sugar
solution. However, they also found a 2-fold decrease
urinary mannitol output (from 20% to 10% urinary
recovery) when compared to control subjects, which
by itself could have accounted for the increased ratio.
Therefore, lactulose/mannitol ratios must be inter-
preted cautiously and analysis of the data for the
individual sugars is required. In addition, possible dif-
ferences in gastrointestinal motility between control
and PD patients groups should be taken into account.
In two studies published in 2011 [5] and 2019 [6],
the mannitol/lactulose test was used with 9 and 6 PD
patients, respectively, and no difference were found in
Fig. 1. Evaluation of intestinal permeability. Urinary excretion of orally ingested non-metabolizable sugars of different sizes provides a
reliable non-invasive in vivo read-out of intestinal barrier function. The mannitol/lactulose ratio evaluates the changes in permeability in
the small intestine. Changes in the colon permeability is assessed with the addition of either sucralose or chromium-labeled EDTA. At the
cellular level, there are two routes for transport of molecules and ions across the epithelium of the gut: across the plasma membrane of the
epithelial cells (transcellular route) and across tight junctions between epithelial cells (paracellular route). This figure was created using
Servier Medical Art, licensed under the Creative Commons Attribution 3.0 Unported License.
S.C.D. van IJzendoorn and P. Derkinderen / Intestinal Barrier in PD S325
the average lactulose/mannitol ratio in urinary sam-
ples taken 24 hours after ingestion of the sugars [5, 6].
The absence of an increase in urinary output of lac-
tulose with a reduced or unchanged urinary output
of mannitol in these three studies argues against an
increased permeability of the small intestine in these
small cohorts of PD patients.
Notably, mannitol and lactulose are most appro-
priate to study permeability changes in the small
intestine. Mannitol and lactulose are fermented by
colonic bacteria, which can make the interpretation
of 24 hours measurements more difficult. This is
particularly relevant for PD patients in which the
composition of colonic bacteria (the microbiome) has
been shown to be different from non-PD subjects
[7]. In order to probe permeability changes in the
large intestine or colon, the addition of an artificial
disaccharide sucralose or chromium-labeled EDTA,
which do not undergo fermentation by colonic bac-
teria, is more suitable [8, 9]. When applied to 6 PD
patients, a significantly higher 24 hours—but not 5
hours—urinary excretion of sucralose between PD
and control subjects was observed [6]. Together, the
existing in vivodata on gut permeability in PD suggest
that the colon, but not the small intestine of parkin-
sonian patients is hyperpermeant. It should however
be kept in mind that because of the small sample size
these studies are preliminary and larger independent
surveys are needed to unequivocally demonstrate that
the intestinal barrier is dysfunctional in PD.
An alternative approach to evaluate intestinal bar-
rier function in vivo involves the measurement of
alpha-1-antitrypsin and zonulin in the feces. Alpha-
1-antitrypsin is a protein that is synthesized in the
liver and secreted into the circulation. Detection of
alpha-1-antitrypsin in the feces reflects its loss to
the intestinal lumen and, indirectly, is a measure of
mucosal barrier integrity. Zonulin is a tight junction-
associated cytoplasmic protein and increased fecal
concentrations have been associated with disruption
of the mucosal barrier [10]. Schwiertz and colleagues
[11] applied this approach to 36 PD patients and
28 control subjects and reported that significantly
more PD patients (27 out of 36) than control subjects
(8 out of 28) showed increased levels of alpha-1-
antitrypsin in the feces. In addition, significantly
more PD patients (16 out of 36) than control sub-
jects (4 out of 28) showed increased levels of zonulin
in the feces. The discrepancy between the alpha-1-
antitrypsin and zonulin results and how this relates to
mucosal integrity is not clear ad may reflect differ-
ent aspects of gut wall permeability. Unfortunately,
no direct comparisons between these fecal biomark-
ers and the sugar tests in PD patients have been
reported, which may help in the further validation of
these tests. Notably, the detection of elevated levels of
alpha-1-antitrypsin and/or zonulin in feces, as well as
detected changes in sugar test values, do not discrim-
inate between a perturbation of the mucosal barrier
due to damage to and loss of epithelial cells or due
to dysfunctional tight junctions (discussed below).
Thus far, no studies reported damage to the intestinal
epithelium in PD patients.
Immunolabeling of biopsies
Tight junctions (also known as zona occludens)
play a key role in intestinal barrier function and loss
of tight junction integrity results in increased paracel-
lular permeability of the intestinal epithelium [12].
Transmembrane protein components of tight junc-
tions (e.g., claudins, occludin and junction-associated
molecule (JAM)-A) of neighboring cells engage in
homotypic interactions. These bring the cells in close
proximity to each other while cytoplasmic protein
components (e.g., zona occludens (ZO)-1, -2 and -3,
and cingulin) connect tight junctions to intracellular
machineries (Fig. 2). Comparative Western blot anal-
yses and/or immunolabeling of intestinal biopsies
with antibodies raised against tight junction proteins
are often used to evaluate tight junction integrity
(Fig. 2).
Using western blot, Clairembault and colleagues
[13] showed a 50% reduction in the expression level
of occludin, but not of ZO-1, in lysates of sig-
moid/descending colon biopsies of 31 PD patients
when compared to 11 control subjects. Additional
immunofluorescence microscopy experiments per-
formed on biopsies from 31 PD patients and 8 control
subjects, revealed aberrant subcellular distribution
of occludin and ZO-1 in 22 out of 31 PD patients
(∼70%) as opposed to 2 out of 8 control subjects
(∼20%). Occludin but not ZO-1 showed a more cyto-
plasmic distribution. The severity of aberrant tight
junction protein distribution varied greatly between
patients and was not due to dopaminergic treatment
as also observed in 5 drug-na¨ive PD patients. Perez-
Pardo and colleagues [6] reported a reduction in
the average intensity of ZO-1 immunolabeling in
sigmoid colon biopsies from 6 PD patients when
compared to control subjects. In both studies, only
colonic biopsies and no small intestinal biopsies
were studied. The aberrant subcellular distribution
of tight junction-associated proteins may indicate
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Fig. 2. (A) Composition of tight junctions. Tight junctions (TJs) of epithelial intestinal cells form selective barriers that regulate paracellular
permeability. They consist of proteins including occludin, claudins and Zonula occludens-1 (ZO-1). (B) Representative photomicrographs
of the colonic mucosa labeled with antibodies against ZO-1 and occludin in the colonic mucosa of one control subject and one PD patient;
scale bar: 100m. A normal and typical reticular pattern of occludin and ZO-1 staining was observed in control, while TJs morphology is
disrupted and irregularly distributed in the mucosa in PD. This figure was created using Servier Medical Art, licensed under the Creative
Commons Attribution 3.0 Unported License.
impaired tight junction integrity in the colon of PD
patients. This observation is in line with a recent
report showing that the expression of occludin and
ZO-1 is significantly reduced in PD patient brains
[14]. However, a reduced expression or mislocaliza-
tion of individual tight junction proteins does not
necessarily correlate with perturbed barrier function
[15, 16], and one should thus be cautious with the
interpretation of tight junction protein immunolabel-
ing without supporting functional data.
Ex vivo analyses of barrier function
Epithelial barrier function in mucosal biopsies can
be investigated using Ussing chambers [17]. Clairem-
bault and colleagues [13] used this approach to study
barrier function in colonic tissues of 31 PD patients.
Immunolabeling of the sigmoid/descending colon tis-
sues of this group of PD patients revealed aberrant
subcellular distribution of tight junction proteins (see
above). However, no change in the average paracel-
lular flux of two independent tracers was observed
over a 3-hour time period when compared to controls.
Significant variability however was noted among
individual PD patients. No in vivo gut permeability
assays were performed in this group of PD patients
preventing a direct comparison between in vivo and
ex vivo mucosal permeability.
It should be however kept in mind that mucosal
biopsies only imperfectly reflect the in vivo intestinal
wall. Indeed, these typically lose intrinsic neural input
(e.g., from submucosal neurons) and the luminal con-
tent of the intestine which includes the microbiome.
As both can influence mucosal permeability, it can be
speculated that the increase in colonic permeability
as possibly observed in vivo in PD patients may not
be fully intestinal epithelial cell autonomous, but the
net result of a combination of alterations in intestinal
epithelial tight junction integrity, gut lumen/colonic
bacteria composition and/ or submucosal neurons.
HOW COULD A COMPROMISED
INTESTINAL BARRIER FUNCTION
CONTRIBUTE TO PD PATHOGENESIS?
Based on the topographic distribution of Lewy
bodies and neurites established after autopsy from
PD patients, Heiko Braak hypothesized that PD
pathology may start in the gastrointestinal tract subse-
quently reaching the brain via the vagus nerve. This
is supported by animal studies. Holmqvist and col-
leagues [18] demonstrated that different -synuclein
forms when injected into the intestinal wall of mice
could propagate from the gut to the brain. More
recently, Kim et al. [19] demonstrated gut-to-brain
spread of pathological alpha-synuclein fibrils fol-
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lowing their injection into the mouse muscularis
layer of the pylori and duodenum but not when
the mice were subjected to truncal vagotomy fol-
lowing alpha-synuclein fibril injection. Finally, also
in a bacterial artificial chromosome transgenic rat
model that overexpressed the human alpha-synuclein
encoding gene, gut-to-brain propagation of injected
alpha-synuclein fibrils via the vagus nerve was
demonstrated [20]. Conceivably, the Braak model
requires that the intestinal epithelial barrier should
be porous enough to give way to a hitherto unknown
neurotropic pathogen to trigger alpha-synuclein mis-
folding and aggregation in the nearby enteric neurons
[21]. However, it is also possible that the initial alpha-
synuclein aggregation could take place in the nerve
terminals of the ENS or autonomic nerves in the
gut lining for some other reason unrelated to the
microbiome, pathogens, or a compromised intestinal
barrier. A correlation between gut wall permeabil-
ity and the presence of alpha-synuclein aggregates
was proposed in a mouse model of PD [22] and in
human PD samples [5]. Future studies with larger
patient cohorts should further validate the correla-
tion between tight junction abnormalities and the
presence of alpha-synuclein aggregates in patient
samples. Even in the absence of a specific pathogen,
it might be speculated that the mere increase in
intestinal permeability could be sufficient to expose
enteric neurons to bacterial derived pro-inflammatory
products, such as lipopolysaccaharide (LPS). These
may then induce local inflammation and oxidative
stress and in turn neuronal pathological -synuclein
aggregates. This relatively straightforward scenario is
supported by experimental findings, which showed
that local (intestinal) or systemic administration of
LPS in mice is associated with more alpha-synuclein
expression [6, 22] or aggregation [23]. However, the
underlying molecular mechanisms by which LPS
increases enteric alpha-synuclein levels in these ani-
mal models remain to be elucidated. Indeed, the direct
application of LPS or proinflammatory cytokines to
primary enteric neurons does not increase alpha-
synuclein but instead transcriptionally downregulates
alpha-synuclein expression via a p38 pathway
[24].
Aside from the vagal neuronal pathway, a puta-
tive mechanism by which gut hyperpermeability
may influence the brain in PD include bacte-
rial products that gain access to the brain via
the bloodstream. Systemic inflammation has been
demonstrated in PD patients [25] and evidence from
animal models supports a role for systemic inflam-
mation in the exacerbation of neurodegeneration
[26].
FUTURE PERSPECTIVES
Preliminary results suggest an increase in barrier
permeability of the colon in PD patients. Consider-
ing that a leaky gut may allow factors from the gut
lumen to elicit negative effects on the nerve cells in the
intestine and brain, fortification of the intestinal bar-
rier may provide a novel therapeutic approach in PD.
Such approach has been proposed in other gastroin-
testinal disorders [27]. However, the group sizes in
the existing studies were relatively small and follow-
up studies with larger and treatment-na¨ive PD patient
cohorts are definitely warranted to substantiate these
findings. Such studies would benefit from the parallel
inclusion of multiple permeability tests (e.g., in vivo
triple sugar test and fecal biomarkers, ex vivo perme-
ability test and tissue staining) which allows for the
comparison and further validation of these different
methodologies and for elucidation of the underlying
pathology and mechanisms. They would also ben-
efit from a multivariate and personalized approach
to provide the necessary contextual relevance of
increased gut permeability in the face of an altered
gut microbiome, enteric alpha-synuclein pathology,
inflammation and neurological/motor symptoms.
Reductionist model systems may help to eluci-
date the order of events and causalities between
these parameters, and identify microbes or microbial
factors that may promote alpha-synuclein pathol-
ogy in enteric neurons. Particularly promising is the
use of patient fibroblast-derived induced pluripotent
stem (iPS) cells. The iPSC can be differentiated into
three-dimensional intestinal organoids (mini guts)
[28, 29] as well as to enteric neurons [30, 31].
Three-dimensional epithelial cultures are suitable for
epithelial permeability analyses [32, 33]. Such model
system thus allows for co-culture of mini guts with
enteric nerve cells on the basal side and microbes in
their lumen [34, 35] from the same patient and/ or
control subjects. As with all models, the iPSC model
system has its limitations. For example, iPSC-derived
organoids typically display immature, perinatal char-
acteristics [34] and lack the aging aspect of PD. iPSC
also lack epigenetic aspects that may contribute to
PD. On the other hand, the organoid model system
also takes into account the patient’s genetic back-
ground, a parameter the contribution of which to
mucosal barrier integrity in PD has not been explored.
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